Treatment outcomes of patients on second-line antiretroviral therapy in resource-limited settings: a systematic review and meta-analysis

被引:139
作者
Ajose, Olawale [2 ]
Mookerjee, Siddharth [3 ]
Mills, Edward J. [4 ]
Boulle, Andrew
Ford, Nathan [1 ,5 ]
机构
[1] Med Sans Frontieres, CH-1211 Geneva, Switzerland
[2] Clinton Hlth Access Initiat, Dar Es Salaam, Tanzania
[3] Univ London Imperial Coll Sci Technol & Med, Natl Ctr Infect Prevent & Management, London, England
[4] Univ Ottawa, Fac Hlth Sci, Ottawa, ON, Canada
[5] Univ Cape Town, Ctr Infect Dis Epidemiol & Res, ZA-7925 Cape Town, South Africa
关键词
protease inhibitors; second-line failure; viraemia; virological suppression; SUB-SAHARAN AFRICA; DRUG-RESISTANCE; ROLL-OUT; HIV; MORTALITY; EFFICACY; FAILURE; PROGRAM; COST; LOPINAVIR/RITONAVIR;
D O I
10.1097/QAD.0b013e328351f5b2
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Background: A growing proportion of patients on antiretroviral therapy in resource-limited settings have switched to second-line regimens. We carried out a systematic review in order to summarize reported rates and reasons for virological failure among people on second-line therapy in resource-limited settings. Methods: Two reviewers independently searched four databases and three conference websites. Full text articles were screened and data extracted using a standardized data extraction form. Results: We retrieved 5812 citations, of which 19 studies reporting second-line failure rates in 2035 patients across low-income and middle-income countries were eligible for inclusion. The cumulative pooled proportion of adult patients failing virologically was 21.8, 23.1, 26.7 and 38.0% at 6, 12, 24 and 36 months, respectively. Most studies did not report adequate information to allow discrimination between drug resistance and poor adherence as reasons for virological failure, but for those that did poor adherence appeared to be the main driver of virological failure. Mortality on second-line was low across all time points. Conclusion: Rates of virological failure on second-line therapy are high in resource-limited settings and associated with duration of exposure to previous drug regimens and poor adherence. The main concern appears to be poor adherence, rather than drug resistance, from the limited number of studies accessing both factors. Access to treatment options beyond second-line remains limited and, therefore, a cause for a concern for those patients in whom drug resistance is the identified cause of virological failure. (C) 2012 Wolters Kluwer Health vertical bar Lippincott Williams & Wilkins
引用
收藏
页码:929 / 938
页数:10
相关论文
共 53 条
  • [31] National Research Council, PROT INH MON VERS ON
  • [32] Orrell C, 2007, ANTIVIR THER, V12, P83
  • [33] Osih R, 2008, CHUV RES DAY
  • [34] Impact of Drug Stock-Outs on Death and Retention to Care among HIV-Infected Patients on Combination Antiretroviral Therapy in Abidjan, Cote d'Ivoire
    Pasquet, Armelle
    Messou, Eugene
    Gabillard, Delphine
    Minga, Albert
    Depoulosky, Ayeby
    Deuffic-Burban, Sylvie
    Losina, Elena
    Freedberg, Kenneth A.
    Danel, Christine
    Anglaret, Xavier
    Yazdanpanah, Yazdan
    [J]. PLOS ONE, 2010, 5 (10):
  • [35] Treatment Failure and Mortality Factors in Patients Receiving Second-Line HIV Therapy in Resource-Limited Countries
    Pujades-Rodriguez, Mar
    Balkan, Suna
    Arnould, Line
    Brinkhof, Martin A. W.
    Calmy, Alexandra
    [J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2010, 304 (03): : 303 - 312
  • [36] Reddy E, 2010, 18 INT AIDS C 18 23
  • [37] Renaud-Thery F, 2010, ADULT ANTIRETROVIRAL
  • [38] Renaud-Thery F, 2010, 17 C RETR OPP INF 16
  • [39] Rossouw TMG, 2011, S AFR AIDS C DURB 7
  • [40] Rothstein H, 2009, INTRO METAANALYSIS, P312